1. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases. 1995;26(1):41–46.[PubMed]
2. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron. 1998;79(3):299–305.[PubMed]
3. Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International. 1996;50(5):1694–1699.[PubMed]
4. Andrews NC. Disorders of iron metabolism. The New England Journal of Medicine. 1999;341(26):1986–1995.[PubMed]
5. Ganz T. Molecular control of iron transport. Journal of the American Society of Nephrology. 2007;18(2):394–400.[PubMed]
6. Kooistra MP, Niemantsverdriet EC, Van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJM. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrology Dialysis Transplantation. 1998;13(1):82–88.[PubMed]
7. Maslovsky I. Intravenous iron in a primary-care clinic. American Journal of Hematology. 2005;78(4):261–264.[PubMed]
8. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.[PubMed]
9. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. American Journal of Kidney Diseases. 2001;38(5):988–991.[PubMed]
10. Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration. American Journal of Kidney Diseases. 2003;41(3):651–657.[PubMed]
11. Blaustein DA, Schwenk MH, Chattopadhyay J, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney International. 2003;(87):S72–S77.[PubMed]
12. Blaustein DA, Schwenk MH, Chattopadhyay J, Avram MM. Recent experience with high-dose intravenous iron administration. Kidney International. 2006;70(104):S26–S29.
13. Atalay H, Solak Y, Acar K, Govec N, Turk S. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients. Hemodialysis International. 2011;15(3):374–378.[PubMed]
14. Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Renal Failure. 2002;24(3):307–313.[PubMed]
15. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. Journal of the American Medical Association. 1980;243(17):1726–1731.[PubMed]
16. Auerbach M, Rodgers GM. Intravenous iron. The New England Journal of Medicine. 2007;357(1):93–94.[PubMed]
17. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. On the relative safety of parenteral iron formulations. Nephrology Dialysis Transplantation. 2004;19(6):1571–1575.[PubMed]
18. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrology Dialysis Transplantation. 2006;21(2):378–382.[PubMed]
19. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. American Journal of Kidney Diseases. 2001;37(4):743–749.[PubMed]
20. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. American Journal of Nephrology. 2000;20(6):455–462.[PubMed]
21. Critchley J. Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine. 2007;9:8–36.
22. Eichbaum Q, Foran S, Dzik S. Is iron gluconate really safer than iron dextran? Blood. 2003;101(9):3756–3757.[PubMed]
23. Infed (Prescribing Information) Morristown, NJ, USA: Watson Pharma; 2009.
24. Dexferrum (Prescribing Information) Shirley, NY, USA: American Regent Laboratories ; 2010.
25. Ferrlicit (Prescribing Information) Bridgewater, NJ, USA: Sanofi-Aventis US; 2010.
26. Venofer (Prescribing Information) Shirley, NY, USA: American Regent laboratories; 2007.
27. Feraheme (Prescribing Information) Lexington, Mass, USA: AMAG Pharmaceuticals; 2009.
28. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology. 2000;11(3):530–538.[PubMed]
29. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA Journal. 1996;23(3):319–325.[PubMed]
30. Komolafe JO, Kuti O, Ijadunola KT, Ogunniyi SO. A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. Journal of Obstetrics and Gynaecology. 2003;23(6):628–631.[PubMed]
31. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology. 2004;22(7):1301–1307.[PubMed]
32. Dudrick SJ, O’Donnell JJ, Raleigh DP. Rapid restoration of red blood cell mass in severely anemic surgical patients who refuse transfusion. Archives of Surgery. 1985;120(6):721–727.[PubMed]
33. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. Journal of the American Society of Nephrology. 1998;9(4):664–668.[PubMed]
34. Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Advances in Peritoneal Dialysis. 2000;16:80–84.[PubMed]
35. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. Journal of Laboratory and Clinical Medicine. 1988;111(5):566–570.[PubMed]
36. Case G. Maintaining iron balance with total-dose infusion of intravenous iron dextran. ANNA Journal. 1998;25(1):65–68.[PubMed]
37. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. American Journal of Hematology. 2011;86(10):860–862.[PubMed]
38. NKF-KDOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. American Journal of Kidney Diseases. 2001;37:S182–S238.[PubMed]
39. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. Journal of Laboratory and Clinical Medicine. 1998;131(3):257–260.[PubMed]
40. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. The Lancet. 2007;369(9572):1502–1504.[PubMed]
41. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology Dialysis Transplantation. 2005;20(7):1443–1449.[PubMed]
42. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. American Journal of Kidney Diseases. 1999;33(3):464–570.[PubMed]
43. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Diseases. 1996;28(4):529–534.[PubMed]
44. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Journal of Association of Physicians of India. 2003;51:170–174.[PubMed]
45. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney International. 2005;68(6):2846–2856.[PubMed]
46. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology. 2008;19(8):1599–1605.[PMC free article][PubMed]
47. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology. 2006;26(5):445–454.[PubMed]
48. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. 2005;100(3):c55–c62.[PubMed]
49. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation. 2001;16(5):967–974.[PubMed]
Introduction: Noninvasive measures of bone activity include intact parathyroid hormone (iPTH) and bone-specific alkaline phosphatase (BSAP). Whether BSAP measurement alone or in combination with other biochemical data provides more reliable information about bone turnover than iPTH alone in African Americans on hemodialysis is unknown. Methods: This cross-sectional study aimed to determine the optimal predictor and cutoff points for BSAP, iPTH, calcium and phosphorus in classifying bone biopsy findings. Forty-three African American hemodialysis patients were available for analysis. Biochemical data on the day of biopsy across a spectrum of qualitative histologic bone features were compared. Classification and regression tree analysis was used to determine both the optimal predictor and cutoff points for BSAP, iPTH, calcium and phosphorus in identifying bone turnover status. Findings: Seven subjects had adynamic disease, 31 had mild/moderate hyperparathyroid bone features, and five had severe hyperparathyroid bone disease. BSAP was the optimal predictor of bone biopsy with a cutoff point of 22 ng/mL. Calcium and phosphorus had no predictive value. At BSAP ≤ 22 ng/mL, subjects had either adynamic bone disease or mild/moderate hyperparathyroid bone disease but iPTH was not useful in further classifying biopsy findings. When BSAP was >22 ng/mL, subjects had either mild/moderate or severe hyperparathyroid bone disease, and iPTH was useful in further classifying biopsy findings. With BSAP > 22 ng/mL and iPTH < 726 pg/mL, all subjects had mild/moderate bone turnover features. Discussion: Compared to iPTH, BSAP was shown to be the optimal predictor of biopsy findings with an optimal cutoff at 22 ng/mL.